Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Myriad Genetics Inc
(NQ:
MYGN
)
27.96
+0.30 (+1.10%)
Streaming Delayed Price
Updated: 2:52 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics Inc
< Previous
1
2
3
4
5
6
7
Next >
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
Via
Investor's Business Daily
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
August 13, 2024
Via
Benzinga
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Key Takeaways From Myriad Genetics Analyst Ratings
June 27, 2024
Via
Benzinga
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Avantor Stock Earns 84 RS Rating
July 30, 2024
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results.
Via
Investor's Business Daily
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
May 10, 2024
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today.
Via
InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 08, 2024
Via
Benzinga
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.